Alan J. Lewis, PhD
Dr. Lewis joined as a director in December 2015. He is currently President, Chief Executive Officer and director of Diavacs, a private biotechnology company that offers dendritic cell therapy for autoimmunity and juvenile diabetes, which he joined after serving as Chief Executive Officer and a director of Medistem, a public biotechnology company that is a developer of stem cell therapies, which was acquired by Intrexon Corp. Previously, Dr. Lewis was Chairman, President and CEO of cancer drug developer Ambit Biosciences, which was subsequently acquired by Daiichi Sankyo Company. Prior to Ambit, Dr. Lewis was President and CEO of the Juvenile Diabetes Research Foundation and President and CEO of private stem cell company Novocell. Prior to Novocell, Dr. Lewis served as CEO and a director of Signal Pharmaceuticals until its acquisition by Celgene Cor. Dr. Lewis was then named President of Celgene’s Signal Research division in San Diego, where he directed its integrated drug discovery program in oncology and inflammation and served on Celgene’s corporate executive committee. Dr. Lewis also is on the board of directors for NASDAQ-listed BioMarin Pharmaceuticals, where he chairs the science and technology committee and the board of directors of Scancell Holdings Plc, where he serves on the audit committee and remuneration committee. Earlier in his career, Dr. Lewis held positions of increasing responsibility at Wyeth-Ayerst Research, eventually serving as Vice President of Research with responsibility for 550 scientists and staff. Dr. Lewis has contributed to advancing more than 20 molecules into clinical development and overseeing five investigational drugs that reached the market. He has co-authored over 100 peer-reviewed publications and is an inventor on several patents. Dr. Lewis holds a BSc in Physiology and Biochemistry from Southampton University and a PhD in Pharmacology from the University of Wales. He completed postdoctoral training at Yale University.